Tofacitinib as induction and maintenance therapy for ulcerative colitis

New England Journal of Medicine

Volumn 376, Issue 18, 2017, Pages 1723-1736

  Sandborn, William J ^a   Su, Chinyu ^b   Sands, Bruce E ^c   D'Haens, Geert R ^d   Vermeire, Séverine ^e   Schreiber, Stefan ^f   Danese, Silvio ^g   Feagan, Brian G ^h   Reinisch, Walter ⁱ   Niezychowski, Wojciech ^b   Friedman, Gary ^b   Lawendy, Nervin ^b   Yu, Dahong ^b   Woodworth, Deborah ^b   Mukherjee, Arnab ^b   Zhang, Haiying ^b   Healey, Paul ^b   Panés, Julian ^j  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b PFIZER INC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h ROBARTS RESEARCH INSTITUTE   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PLACEBO; TOFACITINIB; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

AGED; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTESTINE PERFORATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SMOKING; ULCERATIVE COLITIS; ADULT; ANTAGONISTS AND INHIBITORS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; JANUS KINASES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; REMISSION INDUCTION;

EID: 85019133160     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1606910     Document Type: Article

References (25)

1. Ord I Eckmann L Talamini M Baumgart DC Sandborn WJ. Ulcerative colitis. Lancet 2012; 380:1606-19.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
3. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
4. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012; 6: 991-1030.
5. D'Haens G, Colombel J-F, Dubinsky M, Abhyankar B, James A, Lasch K. The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn's disease: Post-hoc analyses from the GEMINI 1 and GEMINI 2 studies. J Crohn's Colitis 2016; 10: Suppl 1: S58.
6. Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am 2014; 43: 603-17.
7. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014; 57: 5023-38.
8. Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777-81.
9. Schreiber S, Rosenstiel P, Hampe J, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002; 51: 379-85.
10. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010; 53: 8468-84.
11. Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016; 310: G155-G162.
12. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-24.
13. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study. N Engl J Med 1987; 317: 1625-9.
15. Mukherjee A, Ito K, Smith MK, Su C, Niezychowski W. The relationship of tofacitinib plasma concentration to clinical efficacy in ulcerative colitis patients in a dose-ranging phase 2 study. Gastroenterology 2014; 146: Suppl 1: S367-S368.
16. Hommel G, Bretz F, Maurer W. Powerful short-cuts for multiple testing procedures with special reference to gatekeeping strategies. Stat Med 2007; 26: 4063-73.
17. Xeljanz (tofacitinib) tablets, for oral use (prescribing information). New York: Pfizer, 2016 (http://labeling .pfizer .com/ShowLabeling .aspx?id=959).
18. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 2008; 35: 139-57.
19. Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-73.
20. Ord I Mould DR Feagan BG Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics- based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
21. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014; 41: 837-52.
22. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, longterm extension study. Arthritis Res Ther 2016; 18: 34.
23. Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psori- asis: A randomized controlled trial. Br J Dermatol 2015; 172: 1395-406.
24. Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised noninferiority trial. Lancet 2015; 386: 552-61.
25. Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: Safety and efficacy in open-label, long-term extension studies over 8 years. Arthritis Rheumatol 2016; 68: Suppl 10. abstract.